<DOC>
	<DOC>NCT01335061</DOC>
	<brief_summary>The purpose of this study will be to determine if a once-weekly prophylaxis regimen of BeneFIX in subjects with moderately severe to severe Hemophilia B is safe and effective.</brief_summary>
	<brief_title>Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Documented history of moderatelysevere to severe hemophilia B (FIX activity &lt;/=2%). Male subjects, aged 12 years to 65 years. Subjects with at least 100 exposure days (EDs) to factor IX products. Subjects with a minimum of 12 bleeding episodes, 6 of which must be joint bleeds, in the 12month period before the Screening visit. Subjects who have received FIX as a primary or secondary prophylaxis regimen within the last 12 months prior to the Screening visit. Subjects who have had major surgery or an orthopedic surgical procedure within the past 3 months prior to Screening visit. Subjects for which major surgery or orthopedic surgery is planned within the duration of study participation. Subjects with a past history of, or current FIX inhibitor, defined as &gt;ULN (upper limit of normal) of the reporting laboratory. Subjects with a known hypersensitivity to any FIX product or hamster protein.</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>on-demand</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>nonacog alfa</keyword>
	<keyword>BeneFIX</keyword>
	<keyword>FIX</keyword>
</DOC>